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Weight group n BMI Weight used for Cy dose Relapse Hazard ratio (95% CI) p-value Overall mortality Hazard ratio (95% CI) p-value
Non-obese
120% IBW
72 25 (19-28) ABW 1.00 1.00
Obese
121-149 IBW
46 29 (24-42) ABW 0.97 (0.55-1.74) 0.68 0.72 (0.37-1.4) 0.34
Morbidly obese
 150 IBW
29 36 (30-55) IBW + 0.5 (ABWeIBW) 0.78 (0.39-1.57) 0.32 0.65 (0.28-1.52) 0.32
IBW ideal body weight, ABW actual body weight.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S127eS146S130using ABW50 formula in morbidly obese receiving high-dose
Cy/TBI conditioning. Our data indicate that adjusted Cy
dosing yields similar relapse rate, OS and NRM with no sig-
niﬁcant impact on engraftment or toxicity. Morbidly obese
patients can safely receive adjusted dose Cy.Figure 1B. Overall survival.
Figure 1C. Landmark analysis for PFS after 1 yr of HR.
Figure 1A. Progression free survival.142
Outcome of Patients with Systemic Light Chain (AL)
Amyloidosis with Concurrent Renal and Cardiac
Involvement
Talha Badar 1, Simrit Parmar 2, A. Megan Cornelison 3,
Nina Shah 2, Qaiser Bashir 2, Krina Patel 2, Chitra Hosing 2,
Uday R. Popat 2, Richard E. Champlin 2, Muzaffar H. Qazilbash 2.
1 Leukemia, University of Texas MD Anderson Cancer Center,
Houston, TX; 2 Stem Cell Transplantation and Cellular Therapy,
The University of Texas MD Anderson Cancer Center, Houston,
TX; 3 UT MD Anderson Cancer Center, Houston, TX
Background: Light chain amyloidosis (AL) involves deposi-
tion of misfolded amyloid ﬁbrils in the affected organs,
including heart and kidneys, causing organ dysfunction. We
sought to determine if the concurrent cardiac and renal
involvement was associated with a worse outcome than
either organ alone.
Methods: We identiﬁed 129 patients (pts) with AL who
received high-dose chemotherapy followed by autologous
hematopoietic stem cell transplantation (auto-HCT) at our
institution between 1997 and 2014. Ninety-nine patients had
either renal (group 1: n¼62, 62%), cardiac (group 2: n¼20,
20%) or both renal and cardiac (group 3: n¼17, 17%)
involvement. Hematologic response (HR) was deﬁned ac-
cording to the international myeloma working group
(IMWG) criteria and organ response (OR) was deﬁned ac-
cording to consensus opinion from the 10th international
symposium on amyloid and amyloidosis (M Gertz et al. Am J
Hematol. 2005 Aug; 79[4]:319-28).
Results: The median age at auto-HCT for groups 1, 2 and 3
was 58, 60, and 53 years, respectively (p ¼ 0.30). The
median urine protein in groups 1, 2 and 3 was 5.5, 0.28
and 2.0 g/24h, respectively (p ¼ <0.0001). The medain
difference in involved and uninvolved free light
chain(dFLC) in groups 1, 2 and 3 was 37, 147 and 128,
respectively (p ¼ 0.10). The medain NT-Pro BNP (pg/ml) in
groups 2 and 3 was 1206 and 1766, respectively (p ¼ 1.0),
and median intraventricular septal thickness (cm) was 1.3
and 1.4, respectively (p ¼ 0.87). Mayo Cardiac stages for
patients in groups 2 and 3 were: stage 1; 4 (11%), stage 2;
13 (35%), stage 3; 7 (19%) and unavailable; 13 (35%).The
median time from diagnosis to auto-HCT in groups 1, 2
and 3 was 7 (2-120), 8 (3-35) and 6 (3-96) months,
respectively. The overall hematological response rate
(CR+VGPR+PR) in groups 1, 2 and 3 was 75%, 87.5% and
82% respectively (p ¼ 0.38). Organ response in groups 1, 2
and 3 was 40%, 40% and 70% respectively (p ¼ 0.002). Four(6%) patients in group 1, 0 in group 2 and 1 (6%) patient in
group 3 died of non-relapse causes (NRM) in the ﬁrst 100
days (p ¼ 0.66). The median progression free survival (PFS)
from auto-HCT in groups 1, 2 and 3 was not reached, 19.5
months, and 21 months respectively (p ¼ 0.035) (Fig. 1A).
The median overall survival (OS) in groups 1, 2 and 3 was
10, 4.3 and 5 years, respectively (p ¼ 0.035) (Fig. 1B). In a
landmark analysis for patients who were alive and in HR
at 1 year post auto-HCT, the median PFS in groups 1-3
was not reached, 37.5 and 21 months, respectively (p ¼
0.16) (Fig. 1C).
Conclusion: Patients with concurrent cardiac and renal AL
have similar PFS and OS as patients with cardiac AL alone, but
worse than patients with renal AL only. These patients may
potentially beneﬁt from auto-HCT.
